

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	("5464758").PN.	US-PGPU B; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/08 12:28
L2	1426	Estrogen receptor?	US-PGPU B; USPAT; EPO; JPO	ADJ	ON	2004/12/08 12:29
L3	27	L2 AND single nucleotide polymorphism?	US-PGPU B; USPAT; EPO; JPO	ADJ	ON	2004/12/08 12:29

	<b>Title</b>	<b>Current OR</b>	<b>Current XRef</b>
<b>20</b>	Gene sequence variances in genes related to folate metabolism having utility in determining the treatment of disease	514/1	435/6
<b>21</b>	Pin1 as a marker for abnormal cell growth	435/6	435/7.23
<b>22</b>	Microarray methods utilizing semiconductor nanocrystals	435/6	435/7.92
<b>23</b>	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium	514/179	514/182
<b>24</b>	Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing	435/6	702/20
<b>25</b>	Estrogen receptor beta variants and methods of detection thereof	536/24.3	435/6; 435/91.2; 536/23.5; 536/24.31; 536/25.32
<b>26</b>	Tumor necrosis factor receptor 2	536/22.1	435/6; 435/91.1; 435/91.2; 536/23.1; 536/24.3; 536/24.31; 536/24.33
<b>27</b>	Colon cancer marker	435/69.1	435/320.1; 435/325; 435/70.1; 536/23.1; 536/23.5

	<b>Title</b>	<b>Current OR</b>	<b>Current XRef</b>
<b>1</b>	Neurotransmission-associated proteins	435/6	435/320.1; 435/325; 435/69.1; 530/350; 536/23.5
<b>2</b>	ESTROGEN RECEPTOR BETA VARIANTS AND METHODS OF DETECTION THEREOF	435/6	435/320.1; 435/325; 435/69.1; 530/350; 536/23.5
<b>3</b>	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium	514/170	
<b>4</b>	Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing	435/6	530/350; 536/24.3
<b>5</b>	Nucleic acid-associated proteins	435/6	435/199; 435/320.1; 435/325; 435/69.1; 536/23.2
<b>6</b>	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium	514/170	514/406
<b>7</b>	Secreted proteins	514/12	435/320.1; 435/325; 435/6; 435/69.1; 530/350; 536/23.5
<b>8</b>	Drug metabolizing enzymes	435/6	435/183; 435/320.1; 435/325; 435/69.1; 530/388.26; 536/23.2

	<b>Title</b>	<b>Current OR</b>	<b>Current XRef</b>
<b>9</b>	Proteases	435/6	435/226; 435/320.1; 435/325; 435/69.1; 530/388.26; 536/23.2
<b>10</b>	Proteins and nucleic acids encoding same	435/6	435/183; 435/320.1; 435/325; 435/69.1; 536/23.2
<b>11</b>	Genetic analysis for stratification of cancer risk	435/6	435/287.2
<b>12</b>	Interactions between AR, ER, TR2, and TR4	435/7.1	514/12
<b>13</b>	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer	435/6	435/7.23
<b>14</b>	Methods of treating and preventing bone loss	435/4	435/6; 514/102; 514/12; 514/182
<b>15</b>	Diagnostic markers for breast cancer	435/6	435/91.2; 536/23.2
<b>16</b>	Pin1 as a marker for abnormal cell growth	435/6	435/7.23
<b>17</b>	Novel nuclear receptor corepressor molecules and uses therefor	435/6	435/320.1; 435/325; 435/69.1; 530/358; 536/23.5
<b>18</b>	Estrogen receptor alpha variants and methods of detection thereof	435/69.1	435/320.1; 435/325; 530/350; 530/388.22; 536/23.5
<b>19</b>	Combination therapy for the treatment of estrogen- sensitive disease	435/7.23	514/171; 514/651